62nd National Congress of the Hungarian Society of Laboratory Medicine, Szeged, Hungary, August 28–30, 2025

President of the Congress Imre Földesi Scientific Organizing Committee János Kappelmayer Contents Abstracts Oral Communications Plenary Lectures Hematology diagnostics section SE1.1-6 Endocrinology and new biomarkers section SE2.1-5 AI and congenital disorders section SE3.1-6 Laboratory testing of drug effects section SE4.1-5 Varia section SE5.1-6 Autoimmunity and allergy tests section SE6.1-6 Symposium – Abbott CS1.1-2 Symposium – 77 Elektronika CS2.1-2 Symposium – Biomarker CS3.1-2 Symposium – Diagnosticum CS4.1 Symposium – Beckman Coulter CS5.1-3 Symposium – AstraZeneca CS6.1-2 Symposium CS7.1 Poster Presentations Poster section - I PS1.1-15 Poster section - II PS2.1-12 Poster section - III PS3.1-16 Poster section - IV PS4.1-13 Author index ORAL PRESENTATIONS Abstr. Nr. SE1.1 Applicability of laboratory algorithms at a university laboratory in anemia and body fluid analysis Hevessy Z., Kürti G.-Szabó E., Baráth S., Bartha-Tatár A., Tóth G., Kappelmayer J. Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Background: We have developed previously a complete and efficient algorithm for laboratory medicine physicians for the differential diagnosis of anemia. We have also introduced an algorithm for cell counting in body fluids (BF) recently. We aimed to test the applicability of these algorithms in the routine workflow. Methods: We collected the HGB and RETI% results measured at the Department of Laboratory Medicine of the University of Debrecen in 2023 from the laboratory information system (LIS) database. Last year 297 samples were investigated for thalassemia, their laboratory results were collected from LIS. Turnaround time (TAT) was calculated from LIS data in a period before and after the introduction of the new BF algorithm. Results: We found that 16.7% of men (5,495), 16.9% of non-pregnant women (NPW) (7,261), and 27.4% of pregnant women (PW) (825) had HGB levels below the WHO-defined anemia threshold. The number of anemic patients who had RETI% ordered was low, with only 19.9% of anemic men (1,096), 18.9% of anemic NPW (1,371), and 1.45% of anemic PW (12). On the other hand, 51% (944) tests in NPW and 76% (1359) RETI% tests in men were carried out in non-anemic individuals. In case of thalassemia investigation, low MCV was detected in 54% of samples, iron panel could be performed in 30% of patients and those patients having HbA2>3.5% had HBB gene alteration in 90%. With the new BF algorithm routine TAT median of WBC in CSF decreased to 31 min from 84 min and emergency TAT median to 33 min from 78 min (p<0.001) and percentage of outliers decreased dramatically. Conclusion: Most anemic patients do not have a RETI% result, on the other hand, a significant proportion of RETI% measurements were performed in non-anemic individuals. Pop-up windows in the clinical medical system could aid clinicians in navigating the next step in the anemia investigation based on the algorithm. The new BF algorithm decreased the number of samples that need to be counted by microscopy and TAT decreased drastically. Abstr. Nr. SE1.2 Quality control on hematology cell counters by accreditation requirements and guidelines Szakony S., Szurovecz M., Zemplenyi M. Central Laboratory, South Buda Central Hospital, St Imre University Teaching Hospital, Budapest, Hungary Background: The ISO 15189 accreditation standard pays special attention to ensuring the validity of examination results. Accomplishing this in hematology cell counters is not as simple as in clinical chemistry. The International Council for Standardization in Hematology (ICSH) published a guideline in 2024 to help laboratories develop quality control (IQC) policies. Our laboratory has previously used several methods in hematology IQC, and we have refined these by the guidelines. Methods: We have determined the manufacturer's commercial control's measurement frequency, target value, and action limits. We also employ other forms of IQC: retained fresh patient specimens, patient moving averages, delta-checking with previous patient results, and verification of cell counter results by blood film examination. The results are recorded partly in the IQC program, an Excel spreadsheet, and a laboratory information system (LIS). Results: The clinically important parameters of the commercial control are plotted on a Levey-Jennings graph at 3 levels (WBC, RBC, Hb, MCV, PLT) and evaluated using a trend analysis or rule-based system. However, this is not sensitive enough, so we use retained fresh patient specimens daily to assess imprecision and weekly for inter-instrument comparison. The patient moving averages detect drift between control runs. Delta-check helps to detect pre-analytical errors. Abnormal hematological parameters are evaluated through blood film examinations. Hematology supervisor periodically reviews documentation. Conclusion: The IQC policy developed based on the ICSH guideline enabled the continuous coordination of the two hematology automated systems, used in the laboratory, operating on different principles, the early detection of emerging problems and the timely initiation of troubleshooting, the daily verification of the precision limits specified by the manufacturer, and the fine-tuning of the blood film examination algorithm. Abstr. Nr. SE1.3 False-Positive HIL Index: How It Can Lead to the Diagnosis of a Malignant Hematologic Disorder Batik D., Babarczy E., Gőcze P. Győr-Moson-Sopron-County Petz Aladár University Teaching Hospital, Győr, Hungary Background: Hemolysis, icterus, and lipemia (HIL) are the most common sample integrity issues that can interfere with laboratory testing. They may lead to erroneous results and, ultimately, inappropriate medical decisions. In automated systems, visual HIL index verification is often omitted, and reliance is placed solely on the automated results. Method: We present two case studies demonstrating how falsely elevated lipemia or hemolysis indices can lead to the diagnosis of hematologic disease. The first case involved a 45-year-old female patient admitted to the emergency department with splenic rupture, while the second case involved a 75-year-old female patient with a wrist fracture. Blood samples were sent to the emergency laboratory. Complete blood count analysis was performed on a Sysmex XN-1000 analyzer, and chemical testing was conducted on a Siemens Atellica CH 930 module. Results: The chemical analyzer's HIL index indicated two crosses (++) for lipemia in one case and three crosses (+++) for hemolysis in the other, yet visual inspection revealed both samples to be completely homogeneous. Due to the discrepancy in HIL indices, the laboratory ordered additional tests, including total protein, immunoglobulins, and serum protein electrophoresis. After consulting with the attending surgeon, preliminary suspicion of a malignant hematologic disorder was raised. Conclusion: The discrepancy between the HIL index and visual serum inspection may reveal an underlying malignant hematologic condition. A simple observation can quickly raise suspicion of a hematologic malignancy. Thus, even a central laboratory in a hospital can provide crucial support to clinicians in early detection. Abstr. Nr. SE1.4 Challenges in the Evaluation of Variants of Unknown Significance in Hematological Malignancies Andrikovics H., Csabán D., Benedek-Szabó F., Bors A., Őrfi Z. Laboratory of Molecular Genetics, Central Hospital of Southern Pest – National Institute of Hematology and Infectious Diseases, Budapest, Hungary In the field of oncohematology, there are currently no universally accepted international guidelines regarding including variants of unknown significance (VUS) in diagnostic reports generated by next-generation sequencing (NGS). This study reevaluates previous NGS findings using consensus reference variant lists derived from large-scale studies and compares them to automated classification algorithms designed to evaluate somatic mutations. The 59-gene consensus myeloid NGS panel was utilized (CLC Genomics Workbench 21, Golden Helix - VSClinical). The ClinGen/CGC/VICC, WHO, ComPerMed Expert Panel, and NCCN guidelines were used to determine the clinical significance of identified variants. Clinical samples (n=467) from 443 patients with suspected or confirmed oncohematological diseases involved 17,102 variants (755 oncogenic/likely oncogenic; 471 variants of unknown significance, and 15876 benign by the Golden Helix – VSClinical automated variant classification). Classification remained unchanged for 98% of variants (n = 16,687). A total of 120 variants initially classified as VUS were reclassified as clinically significant, 91 of them based on evidence reported by WHO and NCCN guidelines (e.g., frameshift variants in ASXL1, CEBPA, BCOR, and NPM1 genes). Classifying somatic variants can be challenging. In response, the UK NEQAS launched the "Pathogenicity of Hematological Neoplasia Variants" pilot survey and external quality control program in 2023, aiming to standardize the interpretation of genetic variants in hematological malignancies. While the 98% concordance rate is reassuring, reclassifying even a small percentage of VUS to clinically relevant findings highlights the importance of periodic data reevaluation. Continuous monitoring of comprehensive clinical and functional research studies is essential for reclassifying variants of unknown significance. Abstr. Nr. SE1.5 Laboratory evaluation of glucose-6-phosphate dehydrogenase enzyme activity in Hungary Fejes Z.1, Kürti G.-Szabó E.1, Nagy O.1,2, Balogh I.1,2, Hevessy Z.1, Kappelmayer J.1 1Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. 2Divison of Medical Genetics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Background: Glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency is one of the commonest enzymopathies worldwide (over 500 million people are affected). In G6PD deficiency, less NADPH are generated in red blood cells making them more vulnerable to oxidative stress induced by antimalarial drugs (e.g. primaquine) or other medications (e.g. antibiotics, NSAIDs), that may trigger acute hemolytic anemia (AHA) in such patients. Our goal was to evaluate the results of G6PD measurements and estimate the prevalence of G6PD deficiency in Hungary. Methods: G6PD activity was measured spectrophotometrically using an enzymatic quantitative assay in a total of 96 patients (54 males, 39 infants and 57 adults) with suspicion of non-immune mediated anemia, malaria infection or intravascular hemolysis. G6PD gene variants were retrospectively investigated by bioinformatic reanalysis of a 5-year period of sequencing data. Results: Based on the enzyme activity results, out of the 96 clinical samples we detected 2 patients with G6PD deficiency (<10%) and 2 others showed decreased G6PD level (58 and 60%, respectively). Among the 701 genetically tested patients, we found 3 patients with a Class-II pathogenic G6PD variant in exon11 (p.Arg454Cys), which may trigger AHA after oxidative stress. A 19-year-old Nigerian male patient with fever, abdominal pain, and weakness was diagnosed with Plasmodium ovale infection. Due to the markedly reduced G6PD enzyme activity (6%), he received extended administration of reduced dose of primaquine, and drug induced AHA was not developed during the observation period. Conclusion: Although G6PD deficiency is a rare genetic disease in Hungary (estimated prevalence is <1%), the increasing number of affected ethnic groups makes it reasonable to measure enzyme activity as a screening laboratory test. Abstr. Nr. SE1.6 Autoimmune Hemolytic Anemia caused by Streptococcus pneumoniae Infection – A Case Report Tomán A1, Csapody M.2, Szabó C.2, Bekő G.1 Bethesda Children's Hospital, Central Laboratory1, Intensive Care Unit2, Budapest, Hungary Background: Autoimmune hemolytic anemia (AIHA) is a rare, acquired condition caused by antibodies targeting antigens on red blood cells. In the cold type, these antibodies become active at lower temperatures. Diagnosis is based on clinical history, symptoms, and laboratory findings consistent with hemolysis. Methods and Results: We report the case of a 1-year-old girl admitted to our intensive care unit due to respiratory failure. Her illness began five days before with upper respiratory symptoms and followed by fever three days later. Streptococcus pneumoniae antigen was detected in the pleural fluid. Laboratory tests revealed anemia, moderate thrombocytopenia, elevated acute phase proteins and LDH, prolonged APTI, low albumin and total protein. Due to rapid deterioration, she required invasive respiratory support. Her blood count showed a drastic decrease in hematocrit and platelet count within 12 hours, and cold agglutinins appeared in the blood smear. Neurological symptoms, the fact of pneumococcal infection, and anemia raised the possibility of p-HUS. The presence of cold agglutinins, absence of schistocytes, normal renal function, and hepatosplenomegaly supported the diagnosis of AIHA. An unusual aspect of the disease course was that, despite suspected intravascular hemolysis, serum bilirubin levels remained within the normal range throughout. High-dose methylprednisolone therapy was initiated as treatment. The Mycoplasma IgM titer was initially elevated; however, based on the subsequently low IgG levels, an acute Mycoplasma infection was ultimately ruled out as the underlying cause. Conclusion: Our patient showed a progressive clinical and laboratory improvement on intravenous therapy and was successfully extubated on the seventh day of treatment. At another hospital she underwent decortication and lung resection, after which the air leak resolved. Due to her hematologic condition, she remains under hematology follow-up. Abstr. Nr. CS1.2 Investigation of blood biomarkers for the management of traumatic brain injury (TBI) Bencze D.1, Bíró L.2, Sütő R.3, Pócsi M.1, Kappelmayer J.1, Nagy B. Jr.1 1Department of Laboratory Medicine, 2Gyula Kenézy Campus, Emergency Medicine Unit and 3Intensive Care Unit, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Background: Assessment of blood biomarkers represents a relevant approach to identify patients at risk for intracranial injury requiring computed tomography (CT) examination. Protein S100 beta (S100B) is a well-known TBI biomarker but has a relatively short half-life. Combined measurement of astrocytic glial fibrillary acidic protein (GFAP) and neuroaxonal marker ubiquitin carboxyterminal hydrolase L-1 (UCH-L1) has recently been introduced to aid the clinical diagnosis of mild TBI within 12 hours of trauma. Methods: In this study, 41 TBI patients having Glasgow Coma Scale (GCS) score of 3-15 were enrolled at the age of 59.1 ± 21.3 years (11 females and 30 males). Serum GFAP, UCH-L1 and S100B at admission were analyzed on an Architect® i1000SR (Abbott) and a Liaison® XL (DiaSorin) instrument, respectively. Diagnostic characteristics of these biomarkers were statistically evaluated, and their levels were correlated with TBI severity based on CT positivity and GCS scores. Results: Significantly (p<0.001) higher concentrations of GFAP (2896 [161-8455] vs. 36 [20-71] ng/L), UCH-L1 (3398 [386-8079] vs. 446 [285-682] ng/L), and S100B (2.38 [0.42-4.90] vs. 0.22 [0.11-0.35] μg/L) were measured in patients with positive CT scan compared to those with negative result. A significant inverse correlation was found between GFAP and GCS values (r=-0.405, p=0.010). According to ROC-curve analysis, baseline GFAP was the most effective among these biomarkers to indicate clinically significant TBI with a substantial AUC value of 0.928 (p=0.0009). Using the official GFAP cut-off value of 35 ng/L, 100% sensitivity and 48.6% specificity was determined. Conclusion: Based on our preliminary data, GFAP and UCH-L1 can routinely contribute to accelerated diagnosis of TBI. Abstr. Nr. SE2.1 Macro-TSH screening in daily practice Szurovecz M., Szűcs J., Szakony S. Central Laboratory, South Buda Central Hospital, St Imre University Teaching Hospital, Budapest, Hungary Background: The issue of macro-TSH has been raised in the scientific literature for the past two decades, but only recent reviews have been published to investigate it. Hormone replacement therapy for subclinical hypothyroidism is usually started when the TSH level is above 10 mIU/L, therefore, it is crucial to identify cases of elevated TSH levels due to macro-TSH or other potential laboratory interferences such as heterophile antibodies (HeAbs) and human anti-mouse antibodies (HAMAs). Methods: Among the possible investigation steps, we have chosen two that can be performed in any laboratory: dilution test and precipitation with polyethylene glycol (PEG). In the latter, serum samples are incubated at a 1:1 ratio with a solution of 12.5% PEG. In the case of dilution, a deviation above the measurement uncertainty was considered positive. In the case of PEG precipitation, a PEG-precipitable TSH value above 75% was considered positive. Results: In the first four months of 2025, out of 3300 TSH measurements (Abbott Architect i2000SR), we found 52 cases with results above 10 mIU/L, of which 24 cases had subclinical hypothyroidism. Sample dilution and PEG precipitation was performed in 8 cases. There was no difference in sample dilution. All but one of the TSH results that could be precipitated with PEG were above 80%. Conclusion: The laboratory workflow for investigating unusual TSH results should, at a minimum, include a dilution test and PEG precipitation. PEG precipitation is a dependable diagnostic method for identifying macro-TSH. Nevertheless, effective communication between clinicians and laboratory professionals is essential to reduce the likelihood of inaccurately reported thyroid function test results. Abstr. Nr. SE2.2 A methodology for assaying cortisol and cortisone in serum and dried blood microsamples in cooled asphyxiated newborns Csöndör É1, Farkas R.1, Kovács K.2, Dobi M.2, Kerekes R.2, Zsolnai H.2, Vásárhelyi B.1, Szabó M. 2, Karvaly G.B.1 1Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary, 2 Department of Neonatology, Pediatric Center, Semmelweis University, Budapest, Hungary Background: Perinatal asphyxia is a life-threatening event, and whole-body hypothermia combined with intravenous hydrocortisone sodium succinate therapy has proved to be important for the survival of the neonates with hemodynamic instability. As part of a study conducted by the Pediatric Center, Semmelweis University (IF-56-7/2016/EKU), a method was developed to quantitate cortisol (F) and cortisone (E) with the aim to meet the special clinical demands related to the assessment of the glucocorticoid status of these newborns. Methods: F and E levels were evaluated in 50 µL serum or 10 µL capillary dried blood obtained using volumetric absorptive microsampling (VAMS) technology and liquid chromatography–mass spectrometry. Following method validation, assay results were compared in serum and in dried blood technically (n=25), as well as in arterial serum and capillary blood obtained by heel prick in vivo (n=80). Results: In serum, within-run and between-run accuracy were 102-110% and 97-105.6% for F, as well as 97-101% and 96-108% for E. Assay precision was <15%. In VAMS samples, F and E recoveries were 119-143% and 77-109%, respectively, on the day of sample drying (day 0). After keeping samples at room temperature for 7 days, the recoveries were 89-99% and 84-99%. On days 0 and 7, assay reproducibility was 7,2-17,0% and 5,5-5,8% for F and 1,9-17,0% and 5,1-6,9% for E. Strong correlation was observed between serum and dried blood levels (r=0.9075), but, in samples collected from asphyxiated neonates, with large random differences in the case of F, and random as well as systematic differences in the case of E. Conclusion: The method is suitable for assessing cortisol and cortisone concentrations in serum and capillary dried blood microsamples collected from cooled neonates. Abstr. Nr. SE2.3 Our experiences with pancreatic elastase measurement in suspected exocrine pancreatic insufficiency among children Meláth M., Mezei E, Nagy I., Párniczky A. Heim Pál National Pediatric Institute, Budapest, Hungary Background: Pancreatic elastase (PE) concentration measured in faeces is a reliable marker for the evaluation of pancreatic exocrine function. It supports diagnosis and helps to determine the severity in many chronic pancreatic diseases, such as cystic fibrosis (CF), chronic pancreatitis (CP) and other malabsorption syndromes. It is considered to be normal over 200 µg/g of stool. Methods: We performed 745 PE test on the faecal sample of children hospitalized at Heim Pál National Pediatric Institute from September 2020. Tests were based on ELISA method and patients taking pancreatic enzyme replacement therapy (PERT) were not excluded as the used monoclonal antibodies show no cross-reactivity with animal derived elastase-1. There, 685 sample of 745 samples were collected from children previously diagnosed with CF whose PE is under control twice a year. 31 tests were carried out on samples from children with CP or other suspected exocrine pancreatic insufficiency (EPI). We performed 29 measurements due to CF biomarker abnormalities based on newborn screening. Results: We measured pathological PE values in all CF patients except for one. We detected increasing PE levels during the administration of modulator therapy. 2 patients with suspected EPI showed abnormal PE. Of newborns 1 patient was found to have CF diagnosis which was confirmed by PE test. Conclusion: Based on our results, the non-invasive faecal PE test is a reliable and easily accessible diagnostic tool that can contribute to the early detection of EPI and development of an appropriate therapeutic strategy in pediatric patients. Our data show that results should also be considered when evaluating values are between 200-500 µg/g. Abstr. Nr. SE2.4 Analysis of platelet transcripts as potential diagnostic biomarkers for the early detection of lung cancer Balla G.J.1, Pócsi M.1, Lieber A.2, Matolay O.3, Szilárd S.4, Fejes Z.1, Kappelmayer J.1, Nagy B. Jr.1 1Department of Laboratory Medicine, 2Department of Pulmonology, 3Department of Oncology, 4Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Background: Despite the recent development of diagnostic and therapeutic interventions, the incidence of lung cancer remains high. Platelets can advance tumor progress via transferring tumor cell-derived RNAs. Consequently, the RNA content of human platelets is modified in cancer, which is known as tumor-educated platelets. Methods: RNA isolated from leukocyte-depleted platelet samples of newly diagnosed early-and advanced stage lung tumor patients prior to any treatment was analyzed using next-generation RNA sequencing (Illumina). We compared these results to age- and gender-matched healthy controls and COPD patients (n=3/group). Genes showing significant expression changes (FC > or < 1.5) were analyzed by ClueGO (gene ontology). We compared the correspondence of genes with abnormal expression in the histopathological lung and platelet samples of a patient with early-stage lung cancer. Results: In early-stage lung tumors, the level of 524 platelet transcripts increased (e.g. MALAT1), while 119 genes decreased significantly (e.g. GATA3) compared to controls. In advanced stage, 757 genes were elevated (e.g. TP53I3) and 198 showed decreased levels (e.g. RUNX3). Platelet genes with abnormal expression are involved in the regulation of intracellular processes, such as cell activation, vesicle secretion, cytoskeletal rearrangement and transcription regulation. Finally, we identified 65 tumor-derived pathological transcripts (e.g. SERPINE2) in platelets, detectable in both lung biopsy and platelet samples. These genes are involved in stress processes. Conclusion: RNA expression in human platelets is significantly altered in lung tumor acting as a potential new diagnostic test for the detection of pulmonary cancer. Abstr. Nr. SE2.5 The role of molecular genotyping in the differential diagnostic workflow of hydatidiform mole Böjtös I., Tardy E.P., Sarkadi E., Simon J., Fülöp V. Central Hospital of Northern Pest-Military Hospital, Budapest, Hungary Background: Hydatidiform mole (HM) is an abnormal gestational disease with elevated β-hCG level, specific ultrasound, histopathologic and genetic alterations. HM can be classified as complete mole (CHM), with an empty ovum fertilized by diploid or two haploid sperms, and partial mole (PHM) being triploid with one maternal and two paternal genomes. HM can progress into gestational trophoblastic neoplasia, so differentiating HM from hydropic abortion (HA) is of utmost importance in further clinical management. As specific histopathologic markers can give discordant results, defining the genetic background provides the most reliable outcome. Ploidy pattern can be defined by conventional karyotyping, fluorescence in situ hybridization or microsatellite analysis (MS-STR), while specifying the number of the paternal chromosome sets is achieved by analysing the methylation pattern of imprinted genes with methylation specific multiplex ligation-dependent probe amplification (MS-MLPA). The latter two require DNA isolated from fresh or paraffin embedded tissue (FFPE). Methods: 291 cytogenetic analyses were done on fresh products of conception (POC) by standard methods. The introduction of MS-STR and MLPA broadened the diagnostic workflow, facilitating the identification of the paternal genome. 8 FFPE samples were analysed because of ambiguous hystopathology finding. Results: 140 POC sample gave abnormal results. From the 19 HM samples 10 were identified as CHM, 9 were classified as PHM. The analysis of 7 FFPE specimens resulted in clear-cut HM diagnosis, one sample was classified as HA. Conclusion: The most optimal workflow for the differential diagnosis of HM starts with karyotyping fresh POC specimen to distinguish between HA and HM. MS-MLPA enables to define the quantity of the paternal genome. Lacking fresh tissue, genotyping FFPE samples with molecular genetic methods is a highly accurate and integral part of the differential diagnosis in our center. Abstr. Nr. SE3.1 Ethical challenges of innovative medical interventions in the face of artificial intelligence Fodor B. 1,2 1 Borsod-Abaúj-Zemplén County Hospital and University Teaching Hospital, Department of Laboratory, Miskolc, Hungary 2University of Miskolc, Faculty of Healthcare Studies, Miskolc, Hungary The rapid advancement of innovative medical technologies is fundamentally transforming cell-level therapeutic and diagnostic possibilities. Theranostics are opening new horizons in precision medicine, while organoids are becoming indispensable in pharmaceutical research as reliable models mimicking human tissues. The use of quantum dots enables in situ visualization of surgical areas, and lab-on-a-chip systems along with next-generation sequencing technologies are challenging traditional scientific paradigms. The digital revolution and the era of big data have inundated physicians and healthcare professionals with an unprecedented volume of information, presenting significant processing challenges. Regenerative medicine now allows for the growth of organs and even embryonic gene manipulation, with the CRISPR-Cas9 system playing a key role. In parallel, biohackers are developing gene therapy agents in non-traditional, even home-based environments, while research into the digitization of consciousness is intensifying. These technological breakthroughs raise serious ethical concerns. The spread of cyberchondria - health anxiety driven by online information - alongside the tension between technological capabilities and the foundational principles of medical ethics (autonomy, non-maleficence, beneficence, and justice), is becoming increasingly evident. Artificial intelligence-based medical algorithms are gaining a greater role in diagnostic and therapeutic decision-making, prompting a re-evaluation of ethical norms and professional responsibilities. This presentation aims to explore key ethical aspects of modern medical procedures in the face of artificial intelligence. Abstr. Nr. SE3.2 Admission D-Dimer Levels Combined With Artificial Intelligence-Supported Imaging Can Help Predict Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis Kis B.1,2, Orbán-Kálmándi R.2,3, Lóczi L.2,4, Bomberák D.2,3, Hodossy-Takács R.2,3, Szegedi I.2,5, Nagy A6, Kádár A.Z.2,3, Vasas N.1, Berényi E.1, Harston G.7, Csiba L.4,5, Oláh L.5, Bagoly Z.2,3 University of Debrecen, 1Department of Radiology, 2Lendület "Momentum" Hemostasis and Stroke Research Group of the Hungarian Academy of Sciences, 3Division of Clinical Laboratory Sciences, 4HUN-REN-DE Cerebrovascular Research Group, 5Department of Neurology, 6Department of Preventive Medicine, Debrecen, Hungary; 7Brainomix Ltd., Oxford, UK Background: In acute ischemic stroke (AIS), early prognostic markers are crucial to guide treatment decisions. We aimed to assess whether admission D-dimer levels and artificial intelligence (AI)-supported imaging analysis can serve as predictive tools in AIS patients treated